ATE496302T1 - Testmethode zum auffinden von potentiellen medikamenten zur behandlung von entzündungskrankheiten - Google Patents
Testmethode zum auffinden von potentiellen medikamenten zur behandlung von entzündungskrankheitenInfo
- Publication number
- ATE496302T1 ATE496302T1 AT02779724T AT02779724T ATE496302T1 AT E496302 T1 ATE496302 T1 AT E496302T1 AT 02779724 T AT02779724 T AT 02779724T AT 02779724 T AT02779724 T AT 02779724T AT E496302 T1 ATE496302 T1 AT E496302T1
- Authority
- AT
- Austria
- Prior art keywords
- candidate drug
- inflammatory diseases
- testing method
- treat inflammatory
- family
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000012360 testing method Methods 0.000 title 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 2
- 108010057466 NF-kappa B Proteins 0.000 abstract 2
- 102000040945 Transcription factor Human genes 0.000 abstract 2
- 108091023040 Transcription factor Proteins 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000016396 cytokine production Effects 0.000 abstract 2
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 210000000172 cytosol Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006195 histone acetylation Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000030147 nuclear export Effects 0.000 abstract 1
- 230000012223 nuclear import Effects 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0127916.5A GB0127916D0 (en) | 2001-11-21 | 2001-11-21 | Method |
| PCT/GB2002/005255 WO2003046580A1 (en) | 2001-11-21 | 2002-11-20 | Assay for screening candidate drugs for the treatment of inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496302T1 true ATE496302T1 (de) | 2011-02-15 |
Family
ID=9926193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02779724T ATE496302T1 (de) | 2001-11-21 | 2002-11-20 | Testmethode zum auffinden von potentiellen medikamenten zur behandlung von entzündungskrankheiten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7998474B2 (https=) |
| EP (1) | EP1448995B9 (https=) |
| JP (2) | JP5362940B2 (https=) |
| AT (1) | ATE496302T1 (https=) |
| AU (1) | AU2002343063B2 (https=) |
| CA (1) | CA2468082C (https=) |
| DE (1) | DE60239009D1 (https=) |
| DK (1) | DK1448995T3 (https=) |
| ES (1) | ES2362494T3 (https=) |
| GB (1) | GB0127916D0 (https=) |
| WO (1) | WO2003046580A1 (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050390A1 (it) * | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
| US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP2211879B1 (en) * | 2007-10-26 | 2014-05-07 | Brenda E. Moore | Probiotic compositions and methods for inducing and supporting weight loss |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| WO2010091894A2 (en) | 2009-02-16 | 2010-08-19 | Giuliani International Limited | Methods of treating hair related conditions |
| WO2012097207A2 (en) * | 2011-01-13 | 2012-07-19 | The Johns Hopkins University | Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| US20130022575A1 (en) * | 2011-07-19 | 2013-01-24 | Microbial Rx | Systems and methods of replacing intestinal flora |
| GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN103857402A (zh) | 2011-10-11 | 2014-06-11 | 阿基姆医药公司 | 包括厌氧培养的人类肠道微生物群的组合物 |
| CN109999017A (zh) | 2012-02-09 | 2019-07-12 | 诺格拉制药有限公司 | 治疗纤维化的方法 |
| CA3008794C (en) | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| CN104284655B (zh) | 2012-04-18 | 2017-10-27 | 诺格拉制药有限公司 | 治疗乳糖不耐受的方法 |
| WO2013188529A1 (en) | 2012-06-15 | 2013-12-19 | Temple University Of The Commonwealth System Of Higher Education | Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CN104546935A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| AR103260A1 (es) * | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | Modulación inmunitaria |
| AU2018205072B2 (en) * | 2014-12-23 | 2020-05-21 | Cj Bioscience, Inc. | Immune modulation |
| EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| FR3035329A1 (fr) * | 2015-04-23 | 2016-10-28 | Agronomique Inst Nat Rech | La prevention ou le traitement d'une infection par bacteroides thetaiotaomicron |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| WO2017029992A1 (ja) * | 2015-08-17 | 2017-02-23 | 積水メディカル株式会社 | 免疫学的検出方法及びこれに用いるテストストリップ |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN108513545B (zh) | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| ME03487B (me) | 2016-03-04 | 2020-01-20 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI750342B (zh) * | 2016-06-15 | 2021-12-21 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI621708B (zh) * | 2016-06-15 | 2018-04-21 | ４Ｄ製藥研究有限公司 | 免疫調節 |
| TWI782800B (zh) * | 2016-06-15 | 2022-11-01 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| SMT202000695T1 (it) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| JP2021516216A (ja) | 2018-01-19 | 2021-07-01 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | がんを処置または予防するための併用療法 |
| BR112020014565A2 (pt) | 2018-01-19 | 2020-12-08 | 4D Pharma Research Limited | Terapia de combinação para tratamento ou prevenção de câncer |
| MX2020007665A (es) | 2018-01-19 | 2020-09-14 | 4D Pharma Res Limited | Terapia de combinacion para tratar o prevenir el cancer. |
| JP2021510688A (ja) | 2018-01-19 | 2021-04-30 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | がんを処置または予防するための併用療法 |
| WO2019180051A1 (en) | 2018-03-19 | 2019-09-26 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| PL3743086T3 (pl) | 2018-05-11 | 2022-06-20 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| SG11202010958YA (en) | 2018-06-14 | 2020-12-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| SG11202012621VA (en) | 2018-06-19 | 2021-01-28 | 4D Pharma Res Ltd | Dosage form comprising a live biotherapeutic product |
| SI3723777T1 (sl) | 2018-06-25 | 2021-08-31 | 4D Pharma Research Limited | Sestave, ki zajemajo bakterijske seve |
| SG11202100228XA (en) | 2018-07-16 | 2021-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| TW202023590A (zh) | 2018-08-17 | 2020-07-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| US12144834B2 (en) | 2018-09-13 | 2024-11-19 | Xbiome Inc. | Methods and compositions for treating gastrointestinal and inflammatory disorders |
| EP3852775A1 (en) | 2018-09-20 | 2021-07-28 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EA202190876A1 (ru) * | 2018-10-09 | 2021-07-02 | 4Д Фарма Рисерч Лимитед | Композиции, содержащие бактериальные штаммы |
| WO2020079282A1 (en) | 2018-10-19 | 2020-04-23 | 4D Pharma Research Ltd | Compositions comprising bacterial strains |
| WO2020089488A1 (en) | 2018-11-02 | 2020-05-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW202038979A (zh) | 2018-12-12 | 2020-11-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| SG11202106258YA (en) | 2018-12-12 | 2021-07-29 | 4D Pharma Res Ltd | Compositions comprising parabacteroides bacterial strains for treating cancer |
| JP2022511975A (ja) | 2018-12-12 | 2022-02-01 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| EP4495101A3 (en) | 2019-02-08 | 2025-04-30 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| MX2021013776A (es) | 2019-05-10 | 2021-12-10 | 4D Pharma Res Limited | Composiciones que comprenden cepas bacterianas. |
| CA3145904A1 (en) | 2019-07-05 | 2021-01-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP4061389A1 (en) | 2019-11-20 | 2022-09-28 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP3839039A1 (en) | 2019-12-16 | 2021-06-23 | 4D Pharma Research Limited | Providing bacterial biomass with improved storage stability |
| EP3838281A1 (en) | 2019-12-20 | 2021-06-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW202140773A (zh) | 2020-01-27 | 2021-11-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| TW202220639A (zh) | 2020-08-06 | 2022-06-01 | 英商４Ｄ製藥有限公司 | 凍乾方法 |
| TW202225403A (zh) | 2020-11-26 | 2022-07-01 | 西班牙商４Ｄ製藥雷昂有限責任公司 | 方法 |
| US20240148799A1 (en) * | 2021-03-08 | 2024-05-09 | Juntendo Educational Foundation | Composition and ameliorating agent having inflammation reducing effect |
| JP2024540522A (ja) * | 2021-11-19 | 2024-10-31 | ザ・ブロード・インスティテュート・インコーポレイテッド | キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443826A (en) * | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| DE68928665T2 (de) | 1988-08-02 | 1998-11-12 | Gastro Services Pty Ltd | Behandlung von gastro-intestinalen krankheiten |
| US5039703A (en) * | 1989-11-16 | 1991-08-13 | Breuer Richard I | Method for treating inflammatory bowel disorders |
| US5599795A (en) * | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| GB9616047D0 (en) | 1996-07-31 | 1996-09-11 | Glaxo Group Ltd | Medicament carrier with agglomerated large medicament particles and related method of manufacture thereof |
| AU6773598A (en) | 1997-03-26 | 1998-10-20 | Institut Pasteur | Treatment of gastrointestinal disease with ppar modulators |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| US5951977A (en) * | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
| US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20040062757A1 (en) * | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| JP2004528329A (ja) * | 2001-04-18 | 2004-09-16 | メルク エンド カムパニー インコーポレーテッド | 炎症を処置するためのＰＰＡＲα〜γのリガンドまたはアゴニスト |
-
2001
- 2001-11-21 GB GBGB0127916.5A patent/GB0127916D0/en not_active Ceased
-
2002
- 2002-10-31 US US10/285,224 patent/US7998474B2/en not_active Expired - Fee Related
- 2002-11-20 CA CA2468082A patent/CA2468082C/en not_active Expired - Lifetime
- 2002-11-20 AU AU2002343063A patent/AU2002343063B2/en not_active Expired
- 2002-11-20 EP EP02779724A patent/EP1448995B9/en not_active Expired - Lifetime
- 2002-11-20 AT AT02779724T patent/ATE496302T1/de not_active IP Right Cessation
- 2002-11-20 DE DE60239009T patent/DE60239009D1/de not_active Expired - Lifetime
- 2002-11-20 JP JP2003547968A patent/JP5362940B2/ja not_active Expired - Fee Related
- 2002-11-20 ES ES02779724T patent/ES2362494T3/es not_active Expired - Lifetime
- 2002-11-20 WO PCT/GB2002/005255 patent/WO2003046580A1/en not_active Ceased
- 2002-11-20 DK DK02779724.0T patent/DK1448995T3/da active
-
2012
- 2012-09-06 JP JP2012196103A patent/JP2013046615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002343063A1 (en) | 2003-06-10 |
| EP1448995B9 (en) | 2011-10-12 |
| GB0127916D0 (en) | 2002-01-16 |
| EP1448995A1 (en) | 2004-08-25 |
| US20030133875A1 (en) | 2003-07-17 |
| WO2003046580A1 (en) | 2003-06-05 |
| DK1448995T3 (da) | 2011-05-16 |
| DE60239009D1 (de) | 2011-03-03 |
| AU2002343063B2 (en) | 2008-06-05 |
| CA2468082A1 (en) | 2003-06-05 |
| JP2013046615A (ja) | 2013-03-07 |
| ES2362494T3 (es) | 2012-10-05 |
| CA2468082C (en) | 2012-06-26 |
| JP5362940B2 (ja) | 2013-12-11 |
| US7998474B2 (en) | 2011-08-16 |
| JP2005510733A (ja) | 2005-04-21 |
| EP1448995B1 (en) | 2011-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE496302T1 (de) | Testmethode zum auffinden von potentiellen medikamenten zur behandlung von entzündungskrankheiten | |
| Di Caprio et al. | Anti‐inflammatory properties of low and high doxycycline doses: an in vitro study | |
| Hao et al. | Cadmium induces ferroptosis and apoptosis by modulating miR‐34a‐5p/Sirt1axis in PC12 cells | |
| Kuznetsova et al. | Transcriptional and epigenetic regulation of macrophages in atherosclerosis | |
| Bilkei-Gorzo et al. | A chronic low dose of Δ 9-tetrahydrocannabinol (THC) restores cognitive function in old mice | |
| Polizzi et al. | Analysis of the response to two pharmacological protocols in patients with oral lichen planus: a randomized clinical trial | |
| Simonini et al. | The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases | |
| Xuan et al. | Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in beta-amyloid rat model of Alzheimer’s disease | |
| Yu et al. | Baicalin reverse depressive‐like behaviors through regulation SIRT1‐NF‐kB signaling pathway in olfactory bulbectomized rats | |
| Camandola et al. | NF-κB as a therapeutic target in neurodegenerative diseases | |
| Sobeh et al. | Albizia anthelmintica: HPLC-MS/MS profiling and in vivo anti-inflammatory, pain killing and antipyretic activities of its leaf extract | |
| Jin et al. | Minocycline improves postoperative cognitive impairment in aged mice by inhibiting astrocytic activation | |
| Gu et al. | 4‐methoxycarbonyl curcumin: a unique inhibitor of both inflammatory mediators and periodontal inflammation | |
| Youn et al. | HDAC 6 mediates HIV‐1 tat‐induced proinflammatory responses by regulating MAPK‐NF‐kappa B/AP‐1 pathways in astrocytes | |
| Qu et al. | Gallic acid attenuates cerebral ischemia/re-perfusion-induced blood–brain barrier injury by modifying polarization of microglia | |
| DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| DE60034155D1 (de) | Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen | |
| DE60026152D1 (de) | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs | |
| Yang et al. | Galangin inhibits LPS-induced MMP-9 expression via suppressing protein kinase-dependent AP-1 and FoxO1 activation in rat brain astrocytes | |
| Chang et al. | Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression | |
| Lewis et al. | Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T‐cell lymphoma | |
| Gondim et al. | Antinociceptive and anti-inflammatory effects of electroacupuncture on experimental arthritis of the rat temporomandibular joint | |
| DE60019321D1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| Vromman et al. | β‐amyloid context intensifies vascular smooth muscle cells induced inflammatory response and de‐differentiation | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |